Title: Relationship of Natco Pharma LIMITED with Nifty50
Author: NIHAR KUNDAL
Introduction : Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). Our focus is primarily on niche therapeutic areas and complex products. We market and distribute our products in over 50 + countries. We sell our FDF products in the United States, India, Europe and the rest of the world (“RoW”). We also operate in certain key geographies through our subsidiaries.
Natco is using its expertise in organic chemistry to leverage its skillsets and expand into the agrichemical space. After carefully assessing the market potential and understanding its own strengths, Natco is targeting a unique set of molecules for the Indian market, which have a potential to expand to other regions. Natco has also entered strategic alliances with partners who will help in making inroads into the segment. The activities related to the construction of facilities in Nellore area, Andhra Pradesh has been initiated for both active ingredient and crop protection products.
To know more about our Crop Health Sciences division, reach out to 040-23546564
Objectives: To calculate beta and find its significance.
Views & Reviews: Natco Pharma Ltd. is an India-based company engaged in manufacturing active pharmaceutical ingredients.The Company’s segments include bulk chemicals, finished dosage formulations, retail pharmacy and job work charges. The Company’s products in the oncology segment include Desifer, Veenat, Bendit, Bortenat, Lenalid and Clokeran. The Company’s product offerings in the pharma segment include T-Score, PT-MaX, Glatimer, Tarana and Tigi. The Company operates in India, United States of America, Europe and the rest of the world. During the fiscal year ended March 31, 2012 (fiscal 2012), the Company launched Sorafenat 200 milligram tablets, Desifer 100 and 400 milligram tablets, Rasagin 0.5 and 1 milligram tablets and Dorinosa 500 milligram injection in lyophilized form. In November 2012, the Company acquired 51% interest of NATCO Organics Ltd.
Natco Pharma LIMITED Reviews for Investors:
Data Analysis:
Equation: Y= -0.6574 – 0.1034X
Interpretation:
The above equation shows the relation between Nifty50 and Natco Pharma LIMITED.
Return of Natco Pharma LIMITED is dependent variable and return of Nifty50 is independent variable.
Positive sign means if Nifty50 rises by 1 unit then share price of Paradeep Phosphates Ltd will also rise by 0.002285 and vice-versa.
Number of observations are 49.
0.32811 is the t-stat for Y, the p-value for which is 0.74428.
R square is 0.002285 which means 0.22 % of variances in are explained by Nifty.
F is 0.17567, p-value for this is 0.74428 which means model is statistically significant at 1% level.
Conclusion: Beta -0.6574 which is less than 1, it means and Natco Pharma LIMITED that Limited is good for long term investment.
References:
https://www.marketscreener.com/quote/stock/NATCO-PHARMA-LIMITED-33647047/company/